Gyros Protein Technologies’ Immunoassay System to be Incorporated into Jefferson Institute for Bioprocessing’s Curriculum

March 30, 2020

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020, Volume 15, Issue 4
Page Number: 12

The system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.

Gyros Protein Technologies, a Mesa Laboratories company, and the Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University, announced on March 16, 2020 that Gyros’ Gyrolab xPlore immunoassay system will be incorporated into JIB’s curriculum.

According to a Gyros press release, the system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.

“It is essential our courses offer students the opportunity to train using technologies at the leading edge of the field,” said Dr Parviz Shamlou, executive director, Jefferson Institute for Bioprocessing, in the press release. “Real world experience of the Gyrolab platform and kits enable our researchers to graduate with advanced skills that add value in the biopharma industry.”

“While biologics constitute more than 40% of the pharmaceutical industry pipeline, only a few places around the world are dedicated to training the workforce to meet this demand,” added Dan Calvo, president of Gyros Protein Technologies, in the press release. “We are looking forward to working with JIB, a leading specialized training institute in the industry, to integrate Gyrolab technologies within their training programs.”

Source: Gyros Protein Technologies

 

Related Content:

COVID-19 Update